CUV — Clinuvel Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- AU$720.83m
- AU$547.45m
- AU$82.23m
- 96
- 30
- 27
- 53
Annual cashflow statement for Clinuvel Pharmaceuticals, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2019 June 30th | 2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Changes in Working Capital | 0.441 | 0.758 | 0.49 | 0.466 | 2.75 |
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | 18.5 | 14.2 | 19.3 | 39.9 | 36.9 |
| Capital Expenditures | -0.258 | -0.889 | -0.854 | -0.434 | -1.03 |
| Purchase of Fixed Assets | |||||
| Cash from Investing Activities | -0.258 | -0.889 | -0.854 | -0.434 | -1.03 |
| Financing Cash Flow Items | — | -0.018 | -0.044 | 0 | 0 |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -1.03 | -1.49 | -1.48 | -1.5 | -2.24 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 18.1 | 12.5 | 15.9 | 38.8 | 35.3 |